DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Stephens & Co. Maintains Overweight on Recro Pharma, Lowers Price Target to $18

Stephens & Co. maintains Recro Pharma (NASDAQ:REPH) with a Overweight and lowers the price target from $19 to $18.

Benzinga · 03/05/2020 15:21

Stephens & Co. maintains Recro Pharma (NASDAQ:REPH) with a Overweight and lowers the price target from $19 to $18.